Madrigal Pharmaceuticals, Inc. (MDGL) Presents at 44th Annual J.P. Morgan Healthcare Conference TranscriptSeeking Alpha • 01/13/26
Madrigal Expands its MASH Pipeline with Exclusive Global License Agreement for Ervogastat, a Phase 2 Oral DGAT-2 InhibitorGlobeNewsWire • 01/09/26
Madrigal Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 12/15/25
Madrigal (MDGL) Up 21.9% Since Last Earnings Report: Can It Continue?Zacks Investment Research • 12/04/25
Madrigal Pharmaceuticals, Inc. (MDGL) Presents at Jefferies London Healthcare Conference 2025 TranscriptSeeking Alpha • 11/20/25
Madrigal Presents New Data Demonstrating Rezdiffra® (resmetirom) Significantly Improved Multiple Noninvasive Imaging Tests and Biomarkers in Patients with Compensated MASH CirrhosisGlobeNewsWire • 11/10/25
Madrigal Q3 Earnings Miss, MASH Drug Sales Drive Top Line, Stock UpZacks Investment Research • 11/05/25
Madrigal Pharmaceuticals Reports Third-Quarter 2025 Financial Results and Provides Corporate UpdatesGlobeNewsWire • 11/04/25
Biotech is back. Here's why these rallying stocks belong in your portfolio now.Market Watch • 11/03/25
Madrigal (MDGL) Expected to Beat Earnings Estimates: Should You Buy?Zacks Investment Research • 10/28/25
Madrigal to Present New Data from the Company's MASH Program at AASLD's The Liver Meeting 2025GlobeNewsWire • 10/28/25
Madrigal Pharmaceuticals: Rezdiffra Commercialization Bodes Well For Continued GrowthSeeking Alpha • 10/26/25
Madrigal Pharmaceuticals to Release Third-Quarter 2025 Financial Results and Host Webcast on November 4, 2025GlobeNewsWire • 10/22/25
Madrigal Pharmaceuticals, Inc. (MDGL) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)Seeking Alpha • 09/08/25
Madrigal Pharmaceuticals to Participate in Morgan Stanley 23rd Annual Global Healthcare ConferenceGlobeNewsWire • 09/03/25